BAFF CAR-T

DRUG3 trials

Sponsors

Luminary Therapeutics, Paolo Caimi, MD

Conditions

Lymphoma, Non-Hodgkin Lymphoma, B-CellMultiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaMultiple Myeloma RefractoryMultiple Myeloma in RelapseMultiple Myeloma in RemissionNon-Hodgkin LymphomaNon-Hodgkin Lymphoma (NHL)Non-Hodgkin Lymphoma Refractory/ Relapsed

Phase 1

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

RecruitingNCT05312801

Luminary TherapeuticsLymphoma, Non-Hodgkin Lymphoma, B-Cell

Start: 2023-11-21End: 2025-09-02Target: 20Updated: 2024-10-21

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

RecruitingNCT06916767

Paolo Caimi, MDRefractory CLL, Refractory Lymphoma, Relapsed CLL

Start: 2025-07-15End: 2027-12-31Target: 18Updated: 2025-11-10

Phase 2

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Not yet recruitingNCT07771361

Luminary TherapeuticsMultiple Myeloma in Relapse, Multiple Myeloma in Remission, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma +5

Start: 2026-12-01End: 2031-02-01Target: 90Updated: 2026-08-18

Related Papers

Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).

Journal of Clinical Oncology2026-05-27

Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)

Blood2025-11-03